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Abstract 
 
Excitotoxicity is an important and frequently observed neurodegenerative process. Excitotoxicity 
mediates brain damage in a range of diseases and conditions including stroke, and is triggered by 
excessive stimulation of glutamatergic synapses. In spite of extensive studies, the molecular 
mechanisms involved in excitotoxicity following the over-activation of postsynaptic glutamate receptors 
are not well understood, and clinical trials based on our partial understanding of the process ended with 
disappointment. Genetic screens in simple animal models offer a powerful alternative approach, since 
screens are unbiased, analysis is facilitated by strong research tools, and cellular mechanisms are highly 
conserved through evolution. We produced a reliable model for excitotoxicity in the nematode C. 
elegans (the ∆glt-3;nuIs5 strain) and we now use this model to screen for genes whose mutation can 
alter the extent of neurodegeneration. We are using two approaches to systematically knock-
down/modify C. elegans genes and test their involvement in exicitotoxic neurodegeneration: a) We are 
developing sensitive strains that will allow us to use an RNAi library to knock down each gene in the 
nematode’s genome. b) We are using EMS to introduce random mutations throughout the genome. In 
both cases we are monitoring the effect of genetic modification on the level of neurodegeneration. We 
have screened ~2,000 mutagenized genomes and identified 2 mutant strains that show enhanced 
excitotoxicity and 6 mutant strains that show suppression/decrease in the level of neurodegeneration. 
To identify the most interesting mutants, we are carrying out behavioral assays that can indicate if the 
mutation affects overall normal synaptic activity by changing presynaptic release or perisynaptic 
receptor activity. We are mostly interested in mutants where these functions are normal, suggesting 
that the modified levels of neurodegeneration come from a specific effect on postsynaptic cell-death 
pathways. Following the characterization of cell death pathway mutants, we will be using whole genome 
sequencing to identify enhancer or suppressor mutations and study their mechanism of action.  
Introduction 
Glutamate is an excitatory neurotransmitter with a key role in the synapse 
     Glutamate (Glu) is the major neurotransmitter that controls most excitatory signals in the brain {1, 2}. 
In addition to mediating basic neurophysiology, Glu plays a key role in long term potentiation (persistent 
increase in synaptic strength following stimulation of a chemical synapse) and it is important for learning 
and memory {3}.Glu is loaded in synaptic vesicles by a vesicular transporter {4} and gets released from 
presynaptic cells by nerve impulses (stimulation). Once this is done, Glu binds to glutamate receptors 
(GluRs) on the opposing post synaptic neuron. There are two different classes of glutamate receptors: 
metabotropic GluR (mGluRs) and Ionotropic GluR (iGluR). mGluR’s act through G coupled protein 
signaling, with seven membrane-spanning domains that are linked to secondary messengers such as 
cyclic AMP (cAMP) or DAG (Di acyl Glycerol)/IP3 (Inositol-3-phosphate). Ionotropic GluR acts through a 
different mechanism and are divided into 3 different subtypes, each according to the specific Glu-
derived synthetic substance that binds to it (as agonist): NMDA (N-methyl-D-aspartate), AMPA, (α-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate) and Kainate (KA-R) receptors {5, 6, and 7}. Each of 
these receptors have a docking site for Glu and change their conformation once Glu binds, thereby 
leading to the opening of an intrinsic channel domain and influx of Na+ and Ca2+. After Glu activates its 
receptors, it is removed from the synaptic cleft by specialized Glu transporters (GluTs) expressed on the 
cell membrane of cells surrounding the synapse {8}, to maintain homeostasis in the synapse (Figure 1). 
 
 
 
 
 
  
 
 
 
 
  This homeostasis must be maintained to ensure the precision of high-frequency synaptic activity and to 
prevent Glu spillover. The Glu molecules taken up by glia in the surrounding space are converted into 
glutamine (a synaptically inactive molecule), released from the glia, taken up by neurons, and reused 
once again in the presynaptic cells where they are converted back into glutamate and packaged into 
vesicles, in what is referred to as the Glutamate-Glutamine cycle {9-11}. GluTs use a secondary-active 
mechanism by the co-transport of Glu with 3 molecules of Na+ into the cell, and the counter transport of 
potassium (K+) along their electrochemical gradient. Using the gradient of ions established by the 
Na+/K+ ATPase allows the transporter to maintain extracellular concentration of Glu at the nanomolar 
range {12 and 13}. 
 
 
 
Figure 1 
Figure 1: Schematic of a synapse. Glutamate is packaged into synaptic vesicles by specialized 
transporters and fusion of the vesicles to the membrane of the presynaptic cell releases Glu into the 
synaptic cleft. Once Glu is released into the synaptic cleft it quickly binds to its receptors, stimulating 
the opposing post synaptic cell and is quickly removed by Glu transporters (GluT).  
Excessive Glu is Toxic to the brain, as seen during stroke 
     In ischemia there might be an occlusion of a blood vessel, leading to a shortage of oxygen and 
Glucose. Once the supply of energy is depleted, the Na+/K+/ATPase cannot maintain ion gradients, and 
GluTs stops bringing Glu into the cell, resulting in the accumulation of Glu in the synapse as shown in 
(Figure 2).  
 
 
 
 
 
    The excess Glu over stimulates the post synaptic ionotropic Glu receptors (iGluRs), leading to 
excessive depolarization, a buildup of toxic intracellular Ca2+ and Na+ levels, cell swelling and necrotic cell 
death called excitotoxicity {14}.  
 
Stroke damage is caused by excitotoxicity  
     Stroke is the third leading cause of death and the most important cause of long term disability and 
hospitalization in the United States {15}.  Ischemia-triggered excitotoxicity is considered to be the main 
Figure 2 
Figure 2: During Ischemia there is a depletion of energy in the cell resulting in GluTs becoming slow or 
underpowered. This results in the accumulation of Glu in the synapse and over excitability of 
glutamate receptors, leading to toxic buildup of ions inside the cell, which ultimately lead to cell death 
cause of brain damage during stroke. Traumatic Brain Injury (TBI) also induces excitotoxicity, either due 
to the breach of the Blood-Brain Barrier and the penetration of Glu-rich serum into synapses, or by 
mechanically obstructing normal blood supply.  Stroke and TBI related injuries also result in later 
damage to other brain areas, away from the initial site of injury. Patient admission to hospitals grants a 
narrow window of opportunity for therapies that might be able to reduce or slow down the gradual 
deterioration of other areas. However, our understanding of the cascade of events that lead to both 
acute and delayed neurodegeneration is very limited, hindering the effectiveness of current treatment. 
This tells us that we do not completely understand the events that occur during stroke; although current 
treatment provide some measure of relief for the patients, further understanding of the physiological 
processes that occur during stroke is still required. 
 
Stroke and TBI involve a range of forms of cell death mechanisms 
     The stroke core, or center of the affected area in the brain is where a large number of cells undergo 
necrosis, a form of uncontrolled cell death that involves cells emptying their contents into the 
surrounding space, releasing large amount of cytoplasmic Glu and triggering inflammation. Waves of 
destruction propagating from the core to surrounding areas, called stroke Penumbra, resulting in 
delayed death of surrounding neurons. The cells in the penumbra are exposed to a weaker insult and 
undergo a different type of cell death called Apoptosis. This form of cell death is controlled and cells do 
not empty their contents into the surrounding space; thereby reducing the spread of neuronal death 
{16, 17, 18 and 19}.  
  
 
    
     Therefore, there are different forms of cell death that occur during stroke: while necrosis occurs at 
the core of the injury, cells in brain regions surrounding the core die by either apoptosis or necrosis, as 
determined by the spread of Glu and Ca2+.  
 
Race is a factor in stroke risk, although the cause for this is not known 
     Minority populations are the most vulnerable to stroke, most especially African Americans. The 
largest anomaly is seen within the age range of 35-54, with African Americans being four times more 
likely to suffer from stroke during this midlife period and twice as likely to die from stroke when 
compared to Caucasians {20}. The precise explanation for racial differences in the occurrence of stroke is 
not yet known. Lower socioeconomic status, frequently associated with race in the US, has been linked 
with a number of stroke risk factors such as obesity, diabetes, lack of exercise and sharply limited access 
to both routine and acute (in the ER) medical care. However, this is not the full picture because 
Figure 3 
 Figure 3: The red area depicted in the figure above is the center of the affected area which is called the core 
and cells in this area die by necrosis. This form of cell death results in the excretion of Glu into the surrounding 
space, and the propagation of death to surrounding cells. The cells in the outer area are better prepared for this 
shock because they sense the increase in Glu in the surrounding space and die by either Apoptosis or Necrosis 
{17 and 18}. 
Hispanics live in similar conditions, but do not show high incidence of stroke. This tells us that other 
factors causing this higher occurrence of stroke amongst racial minorities are not yet known {21}. 
 
We do not understand the process of neuronal damage in excitotoxicity   
    Several clinical trials have tried to prevent excitotoxic neurodegeneration and ischemic cell death by 
using antagonists that prevent glutamate from binding to post synaptic receptors, but the results were 
highly disappointing. Although this method is feasible and likely to reduce the occurrence of Glu 
mediated over-excitation of GluR’s, a complete block of Glu signaling is apparently very detrimental to 
the cell. This may be due to the function of Glutamate as an excitatory neurotransmitter, makes it 
necessary for neuronal survival, and the viability of the cell depends on normal neuronal activity {22}. 
Therefore it was suggested that Glu plays a crucial role in both protecting the neurons from dying (i.e., 
Glu-mediated Neuro- protection and neuronal loss (i.e., Glu-mediated neurotoxicity) {23}. These clinical 
failures reveal that we need to go back to basic research and understand the next steps in the cell death 
pathway after the toxic buildup of ions in the cell, before we can create drugs that can improve patient 
health rather than dampen it.  
 
Previous techniques such as Proteomic mass spectroscopy and protein-protein 
interaction were good for identifying unknown components of a pathway but 
were subject to their flaws 
      Despite the fact that the first few steps in the cascade of events that occur during excitotoxicity are 
known, the sequence of events that lead to neuronal loss and excitotoxicity remain a mystery {23}. Most 
of the data currently available on excitotoxicity were obtained by taking educated guesses, and were 
limited by the bias of targeted testing. In order to gain an unbiased and comprehensive understanding 
of these mechanisms, molecular events must be studied at the cellular level by using techniques that are 
not limited to identifying only a particular set of candidates. For these purpose different techniques such 
as proteomic mass spectroscopy {24}, genetic analysis and two hybrid screening {25} have been used to 
understand the cellular changes happening in excitotoxicity.  Proteomic mass spectroscopy analyzes 
cellular processes by using protein-protein interactions. Since most proteins interact constantly in the 
cell and enzyme activities are regulated tightly by these interactions, it becomes easy to use one protein 
as an affinity reagent (bait) to isolate its binding partner. Once this interaction is observed, the two 
proteins are isolated and the structure of the unknown protein is deciphered via mass spectroscopy 
{24}. Two hybrid screening uses a similar approach but can also be used to understand DNA-protein 
interaction in addition to protein-protein interaction. This method is used in yeast (Saccharomyces 
Cerevisiae) to identify unknown interactions that occur between proteins or between a proteins and 
DNA {25}. Although both of these methods are very useful for identifying previously unsuspected 
interactions between proteins, they also have their draw backs. One major challenge with this technique 
is that if the physical interaction between the bait and the unknown protein is weak or short lived, or if 
one protein communicates a signal to the other via a soluble small molecule, it will be very difficult or 
impossible to detect this interaction. Another drawback is if the conditions for these two proteins to 
interact are only met at specific time points or conditions. This would hamper or slow down the progress 
of the research, Additionally, these methods are often employed in heterologous cellular system (tissue 
culture or yeast), while the physiological conditions inside the cells of the organism differ significantly 
from the dish or plates where these experiments will be done. 
  
Genetic screens and their unbiased approach 
      Genetic analysis offers an unbiased evaluation of all cellular processes, regardless of prior 
knowledge, or strength of physical interactions between proteins or the brevity of the interaction. 
Moreover, genetic analysis highlights the most important functional interactions, since the modifications 
(caused by the mutations) that result in the strongest effects will be easily identified, due to their strong 
phenotype. Mutations in genes along these cellular cascades can be arranged in logical flowcharts that 
correspond to the sequence of molecular events that lead to the observed phenotypes. Genetic screens 
were the cornerstone of great discoveries made in Drosophila {26}, C. elegans {27} and yeast {28}, 
resulting in improved understanding of key cellular processes. Once key steps that modulate 
excitotoxicity are discovered in nematodes they could potentially suggest neurodegeneration-blocking 
approaches in mammals.  
 
Unique features of C. elegans research make it the system of choice for genetic 
analysis of excitotoxicity: 
       Several genetic studies in C. elegans including apoptosis {29}, synaptic functions {30}, Ras signal 
transduction {31} and RNAi {32}, have led to the discovery of conserved molecules and pathways 
significant to human biology and the subsequent development of therapeutic tactics {33-35}. C. elegans 
as a model for research analysis offers an especially strong combination of research tools. In addition to 
its short life cycle and ease of culturing, all cells have been identified, all neuronal connections have 
been intricately studied, and there is a fully sequenced genome, allowing large scale screens to be 
performed with ease and relatively quick {36, 37, and 38}. Unlike other invertebrates, Glu is the main 
excitatory neurotransmitter in C. elegans, and basic signaling machinery of glutamate synapses in C. 
elegans is very similar to their mammalian counterparts in terms of release mechanism, receptors, 
transporters and their interacting proteins {39- 51}. Our recent studies have shown that key processes 
that occur during excitotoxicity are conserved in nematodes, making our model a suitable candidate to 
study excitotoxicity {52}.  
We created excitotoxic conditions in nematodes by knocking out transporters 
that remove Glu from synapses and combining this with a sensitized mutant 
background 
      To study excitotoxicity in nematodes, we created C. elegans with excessive Glu in their synapse, by 
eliminating glutamate uptake using gene knockouts. Nematodes have a total of 6 glutamate 
transporters genes (glt-1, 3, 4, 5, 6, 7), and we were able to obtain deletion strains for each one of these 
genes by either creating the KO ourselves (glt-3, 4, and 5) or obtaining these strains from the knockout 
consortia (glt-1, 6, 7). Knockout of the genes that express these transporters were obtained via EMS 
mutagenesis and strains that had deletions in these genes were identified via doing PCR {53}. Amongst 
the knockouts obtained via EMS, only mutations in glt-3 led to excessive Glu buildup in the synapse that 
produced excitotoxicity (in the right background, figure 4).  
 
  
Figure 4 is a representation of how many vacuole-like structures were observed in our sensitized 
background alone, and the combination of our glt-3 knockouts with our sensitized background (as seen 
on the right). The bar graph on the right hand corner shows the number of neurons that undergo 
necrosis in the head. These vacuole like structures appear more frequently in our combination strain 
than the single mutant which consisted of our sensitized background alone. To further show that the 
increase in necrotic cell death is as a result of excessive Glu, a knockout of all GluRs were made in the 
presence of our sensitized background as shown on the bar graph on the upper right corner of Fig. 4.  
Figure 4 
     However, the knockout of the transporter alone was not enough to cause exacerbated cell death by 
necrosis. We combined our GluT knockout strain (Δglt-3) with a sensitized background known as nuIs5 
{53} (where GαS*is expressed under a GluR gene promoter), giving rise to our excitotoxicity strain Δglt-
3; nuIs5, where we identified more vacuole like necrotic structures in this transgenic mutant typical of 
neurons dying by necrosis. To ensure that the neuronal death observed in these worms were as a result 
of hyper-activation of post-synaptic receptors by Glu, we used the fact this strain combined the hyper 
active GαS background with a GFP reporter under the promoter of glr-1. A picture of this nematode 
strain is shown below 
 
 
 Figure 5: The picture above shows a worm that has a GαS sensitized background mutation 
fused together with the promoter of glr-1 and a visual reporter (GFP). We can visualize 
neurons in the nerve ring that are stimulated by Glu and undergo Necrosis.  
Figure 5 
     
      
    We also verified that this excessive neurodegeneration is mediated by classical Glu toxicity by 
demonstrating that removing the GluRs from the postsynaptic neurons prevents this neurodegeneration 
even in the presence of excess Glu (in glt-3 KO animals, as shown in figure 4). 
    We now have a powerful system to study excitotoxic neurodegeneration in nematodes, and are well 
positioned to carry out a genetic screen to search for genes whose modification can reduce or enhance 
excitotoxic neurodegeneration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental approaches 
Random Mutagenesis 
    Although genetic screens are invaluable and have proven to be useful in understanding cellular 
processes, they also face several challenges. One major impediment is that they are labor intensive 
especially at the stage of molecular identification of the phenotype-causing mutation by positional 
mapping. Long time periods are required to identify mutations that change the phenotype by examining 
crossovers with chromosomes that harbor known phenotype mutations e.g., dumpy or roll. Although 
advances in technology have introduced the technique of Single Nucleotide Polymorphism (SNP) 
mapping, which allows us to check for crossovers with multiple, easily detectable markers, it is still 
difficult to carry out positional cloning by crosses, and generation of recombinant animals remains 
challenging {54}. Since neurodegeneration requires two genetic modifications (∆glt3; nuIs5), obtaining 
many recombinants while still maintaining these two modifications in the background makes genet ic 
mapping tedious.   
 
     New technological advances, especially in whole-genome sequencing {55}, now allow geneticist to 
circumvent these problems, and prompted us to take this approach to screen for suppressors or 
enhancers of excitotoxicity. 
                                                        RNAi 
    RNA-interference is a method that is used to inhibit the translation of specific mRNAs by introducing 
an inhibitory double stranded RNA (silencing/small inhibitory RNA,siRNA) by feeding worms bacteria 
that produce RNAi targeting specific nematode genes {56}. (figure 6). 
   
  
 
 
 
     Libraries of RNAi-inducing bacteria that consist of most ORF (open reading frames) identified in the C. 
elegans genome are readily available and have been very useful. The main advantage of this approach is 
that unlike classic mutagenesis where mutations are obtained by chance and their location needs to be 
identified, RNAi screens are more methodical (going through each gene one by one); once a phenotype 
is observed, the gene whose silencing is causing this effect will be easy to identify (since the bacteria 
expressing the specific sequence that is producing the RNAi effect is already known). However, until 
recently, a huge roadblock in the use of RNAi screen for neuroscience was that C. elegans neurons 
showed high resistance to effects of RNAi, making most attempts to block neuronal genes with dsRNA 
unsuccessful. 
      Fortunately, in recent years there were major breakthroughs in the use of RNAi for genetic screens in 
C. elegans neuroscience. Several mutations were found to distinctly increase the sensitivity of C. elegans 
Figure 6 
Figure 6 shows a schematic representation of how RNAi is carried out in nematodes. IPTG induces the 
expression of the T7 RNA polymerase; this polymerase only recognizes a specific T7 promoter. A construct 
with the T7 promoter and the gene of interest are inserted in bacteria and fed to nematodes on agar plat es. 
neurons to the effect of RNAi. These sensitizing mutant backgrounds were effectively used to perform 
whole genome RNAi-based screens for neuronal processes {56, 57, 58 and 59}. Several mutant 
backgrounds that increase RNAi sensitivity in neurons are now readily available at the C. elegans 
Genetics Consortium. One such mutation is nre-1, whose mechanism of action in unclear {59}. The other 
is sid-1, a gene encoding part of the cellular RNAi import mechanism {60}. Since sid-1 is normally not 
expressed in neurons, ectopic expression of it (under the pan-neuronal unc-119 promoter) makes 
neurons sensitive to RNAi.   I crossed these two enhancing background RNAi mutations (nre-1; lin-15B 
and P unc-119:: sid-1) with Δglt3; nuIs-5, and I am in the process of analyzing these mutant combinations.  
 
EMS Mutagenesis  
    Ethyl methyl sulfate (EMS) is a mutagenic compound that induces random mutations in genetic 
material by nucleotide substitution. These mutations typically fall in non-coding areas, primarily due to 
introns making up a large part of the genome. The mutagen causes a substitution or change of a single 
nucleotide base, resulting in a codon that produces a different amino acid. These modifications can have 
different effects on protein functions. Most point mutations can render proteins nonfunctional (loss-of-
function (lf) mutation), partially functional (reduction-of-function (rf) mutation), or endow the protein 
with a novel function (gain-of-function (gf) mutation).Other point mutations cause a nucleotide change 
that produces a codon for the same amino acid, and, therefore, these mutations do not change protein 
function at all. Alternatively the mutation might occur in areas that do not affect the protein’s 
configuration. However, genetically strong and important mutations will be identified because they 
show a strong change in phenotype. The technique of EMS mutagenesis has been very useful for genetic 
screens because of its effectiveness to generate different levels of genetic alternations in gene activity. 
Although this technique is very effective at generating genetic changes, it also has its classical 
drawbacks. One of the problems with this method is the high level of difficulty associated with 
identifying phenotype-causing genetic variants. The second problem encountered with the use of EMS is 
the high level of mutagen efficiency; once the animal has been exposed to the mutagen, it most likely 
contains several EMS-induced background mutations in its genome {61 and 62}.  
 
New method in sequencing makes EMS Mutagenesis more attractive       
    Recent technological advances have made EMS mutagenesis screens an effective path to consider. 
This is due to the development of affordable services for whole genome sequencing (WGS), a technique 
that involves sequencing the whole genome and comparing it to a wild type or starting strain reference. 
In this approach, the use of positional mapping is no longer needed as the whole genome is sequenced, 
and the position of the mutation is identified with the aid of software {63 and 64}.  The second problem 
of EMS can be resolved by doing several backcrosses of the mutant strain with the starting strain (∆glt-
3; nuIs5) (as it may be different from the standard wild type, but does not contain the new phenotype 
producing mutations). This is done to get rid of background mutations that were randomly produced in 
the new strain but are not related to the phenotype of interest {65}.  
   
 
 
 
 
 
 
Sorting interesting Mutants from the screen into different groups: Functional 
groups and Complementation groups 
    Mutations can suppress or enhance neurodegeneration by a range of different mechanisms. However, 
some mutant effects are more important to us than others. For example, an overall reduction in Glu 
release is expected to reduce excitotoxicity, but given the evidence from clinical trials that overall 
suppression of Glu signaling is detrimental, reduction in Glu release is not high on our priority list. 
Instead, we want to focus on postsynaptic mechanisms that are specific to excitotoxic cell death. To that 
end, we would like to first sort the mutant strains into categories. The first step in identifying mutants 
with discernable changes in the level of neurodegeneration will be the visual identification necrotic-like 
structures present in the head of our mutant nematode strains and comparing it to our starting 
excitotoxicity strain. By doing this we can visually observe if the mutations have an effect on cell death 
i.e., increase the level of neurodegeneration (enhancer strains) or block/reduce neurodegeneration 
(suppressor strains). Since most mutations are loss-of-function, we expect most suppressor strains to 
carry loss-of-function mutations in death-promoting genes, and most enhancer strain to carry loss-of-
function mutations in neuro-protective genes.  
     Once these mutants are identified via microscopy, the next step is to categorize these mutants into 
different complementation and functional groups. Categorizing these mutants into these groups gives us 
an understanding of how important these mutants are and where in the synaptic functional architecture 
these mutants are producing an effect. We divide our mutants according to their function: pre-synaptic  
(Type 1), peri-synaptic (Type 2), and post-synaptic (Type 3), mutations. 
 
 
 
  
 
 
 
 
Type 1 mutants have alternations in the Presynaptic Cell 
     
    The first group of mutants falls into the category of presynaptic mutations; these mutations affect the 
overall packaging or release of neurotransmitters into the synaptic cleft. The overall mechanism of 
synaptic vesicle release is common to all small molecule neurotransmitter (e.g., Acetycholine, Seratonin, 
and Dopamine): binding of the synaptic vesicle to the SNARE complex, and influx of calcium ions leads to 
vesicle fusion and neurotransmitter release {66}. Since Glu is a compound found in all cells, the only type 
of enzyme that is necessary and sufficient to convert a neuron into a Glu-releasing one is the vesicular 
Figure 7: Schematic representation of how we categorize EMS mutations based on where in the synapse our 
mutation is having an effect. Type 1 mutants have mutations in the pre-synaptic cell and can alter the level of 
neurotransmitter release. Type 2 mutants can either affect the overall expression or activity of GluRs on the 
post synaptic cell or change the expression of GluT transporters that are in close proximity to the synapse and 
are called peri- synaptic mutations. Type 3 mutants will have an effect post-synaptically and alter the activity of 
the receptors or may occur downstream 
Figure 7 
Glu transporters (vGluT) {67}. It should be noted that very large protein complexes are necessary for the 
overall process of synaptic vesicle release to take place, and a mutation in any one of these proteins 
could alter the overall release of neurotransmitters into the synaptic cleft. This category of mutations 
can manifest itself as either a suppressor mutation or an enhancer mutation. Suppressor mutations that 
affect the presynaptic cell can result in the reduction of neurotransmitter release, thereby limiting the 
overall release of glutamate into the synaptic cleft and activation of receptors. Enhancer mutations that 
affect the presynaptic cell might result in the increase in neurotransmitter release, these mutations can 
cause an increase in the level of neurodegeneration as the concentration of Glu in the synaptic cleft is 
increased. This increase in the level of neurodegeneration results in over activation of the receptors and 
increase in the level of excitotoxicity.   
 
 
 
 
 
 
 
 
Figure 8 
B 
Figure 8 A and B are a depiction of how suppressor and enhancer phenotypes can change the amount of readily 
release pool (RRP) of neurotransmitters in the presynaptic cell. Figure 6 A represents an enhancer mutation, 
while figure 6 B shows how a suppressor mutation would manifest itself in the synapse 
A 
  
Using Genetic and pharmacological approaches to identify type-1 (presynaptic) 
mutants  
  Since the underlying mechanism for synaptic release is common to all neurotransmitters, we can 
quantify system wide changes in neurotransmitter release by monitoring acetylcholine (ACh) release at 
the neuromuscular junction (NMJ). In C. elegans this can be easily monitored by doing a drug assay. 
Normally when acetylcholine is released into the synaptic cleft, it binds to its receptor, and is rapidly 
degraded. Aldicarb is a drug that inhibits the enzyme acetylcholine esterase; thereby resulting in the 
buildup of ACh in the synaptic cleft and over activation of its receptors leading to paralysis in worms in a 
typical time frame. As shown in figure 9 mutants with enhance synaptic release will show faster rate of 
paralysis, while mutants with reduced synaptic release will show a slower rate of paralysis. 
 
 
 
 
 
 
  
 
 
 
 
   With the large number of proteins involved in the unified synaptic release mechanism that is common 
to all NTs, we expect most type-1 mutations to affect ACh release as well. However, some mutations 
might specifically affect synaptic vesicle packing of Glu by vGluTs. Fortunately, a mutation in the vGluT 
eat-4 will affect more than the excitatory Glu synapses in the nerve ring. C. elegans also has Glu gated 
chloride channels (GluClβ and GluClα ) {68}, many of which are concentrated in the pharynx; Glu’s main 
function in the pharynx is to cause muscle relaxation in the pharynx muscle, and thus reduce the 
pharyngeal pumping rate. Glu is secreted from M3-neuronal cells in the pharynx onto these Glu gated 
chloride channels on the muscle. Once Glu binds to these receptors, it becomes active and chloride ions 
enter the cell. The reversal potential for chloride is -20mv, this acts as an inhibitory current to lower the 
activity of the cell. Mutations that specifically modify the release of Glu and change the concentration of 
Figure 9 
Figure 9a shows a representation of a wild type synapse and how the enzyme Acetylcholine esterase degrades 
ACh shortly after it is released from the pre-synaptic cell. 9b and b’) Wild-type animals are exposed to aldicarb 
and show paralysis after a certain time period. 9c and c’) mutant worms that show reduced neurotransmitter 
release are exposed to the drug and take longer time periods to paralyze when compared to a wild type strain. 
9d and d’) mutant worms that show increased release of neurotransmitters are exposed to the drug and show 
reduced paralysis time when compared to Wild type. 
Glu in the synapses will also change the amount of Glu available to bind to these channels, resulting in a 
change of pharyngeal pumping rate. This phenotype can easily be detected by counting how many times 
the pharynx pumps within a specific period. 
 
Type 2 mutants: Perisynaptic 
  The second group of mutations we call Peri-Synaptic mutations; these are mutations that affect the 
overall activity of Peri-synaptic proteins, such as changing the level of expression or activity of GluR on 
the post synaptic cells and GluT expressed close to Glu synapses. Mutations that affect the overall 
expression or activity of these GluTs can affect the overall concentration of glutamate in the synapse. 
Mutations that affect the expression, ER/Golgi maturation, trafficking to the cell surface or modulation 
(e.g., by phosphorylation) of receptors at the cell surface, can affect overall sum level of GluR activity. All 
these mutations can affect glutamate signaling in the synaptic cleft by altering either the number or 
activity level of GluRs or GluTs in the synapse, leading to a deviation from normal levels of Glu signaling. 
However, these changes will also affect normal Glu signaling, not only under excitotoxic conditions. The 
schematic below is a representation of this scenario.  
    Studies of GluR trafficking mutants demonstrate that even small changes in the level of activity of Glu 
synapses have clear effects on spontaneous and aversive behaviors mediated by the ASH-regulated 
circuit {69}. Therefore, we can examine if mutants with reduced neurodegeneration achieved that by 
reducing the activity of Glu synapses. In that case the mutants will have modified levels of normal 
activity in Glu synapses, which we can test by monitoring behaviors known to be mediated by these 
cells, such as sensitivity to nose touch. This assay gives us an indication on the overall activity and 
expression of GluR in the synapse. The schematic below shows how we perform Glu signaling assay. 
 
 
  
 
   
   
      
     With this assay we can understand if our mutation affects Glu signaling by following the worm’s 
response to nose touch. An even more sensitive assay that detects small changes in GluR activity levels 
is spontaneous forward-backward mobility, again a behavior delicately regulated by the synapses that 
we study here. The level of nose touch response and spontaneous mobility is also affected by the mere 
survival and overall health of the command interneurons that are subjected to neurodegeneration in 
our study. This adds a potential complication in the interpretation of Glu activity assays. However, a 
mutation that suppresses neurodegeneration by a type-2 perisynaptic mechanism will enhance the 
survival of command interneurons while reducing Glu synaptic activity compared to the starting strain. 
In contrast, a post synaptic death suppressing effect (type-3) will enhance command interneuron 
 Figure 10: The assay is performed by gluing an eye lash to a tooth pick and placing it in front of a moving 
worm (This assay is usually done on young adult worms, i.e., a little past the L4 stage), the worms senses the 
eyelash and a series of events which involve Glu already packaged into vesicles in the presynaptic cell, is 
released into the synaptic cleft. The binding of Glu to its receptors, ion influx and stimulation of command 
interneurons post-synaptically will tell the worm to go backward. 
Figure 10 
survival without reducing Glu synaptic effect (possibly even enhancing nose touch response and normal 
spontaneous mobility) compared to the starting strain. Therefore, a reduced neurodegeneration paired 
with reduced Glu activity suggest type-2 (perisynaptic) mutation, while reduced neurodegeneration 
paired with increased Glu activity suggests type-3 (postsynaptic) mutatiuon. The second group of 
mutants (type 2 or peri-synaptic mutants) again will not be top priority for us as they suppress overall 
Glu signaling, while we want to focus on the postsynaptic death-specific signaling. Again, these 
mutations can definitely tell us important things about Glu signaling, and they do tell us that we are 
doing the screen correctly, but they will not be our first priority.  
 
Type 3 mutations are Post Synaptic 
 
   Mutations in both the Presynaptic (Group 1) and Peri-Synaptic (Group2) categories do not give us an 
intricate insight into the underlying cause of cell death.  The failure of Glu-antagonists during clinical 
trials demonstrated that an overall presynaptic or perisynaptic reduction in Glu signaling is not 
beneficial in the overall picture of excitotoxicity, urging us to focus on death-promoting signaling events 
that occur in the post-synaptic cell as a possible remedy for excitotoxicity. The next categories of 
mutations to which we will devote most of our effort are mutations that have their effect post 
synaptically and affect the activity of the cell death pathway after ion influx. The mutants that fit into 
this category are very important to us as they affect cell death after large amount of ion influx, a 
situation that we observe during excitotoxicity.  However, although mutations that occur post 
synaptically are important, it should be noted that not all of the mutations that fall into this category are 
of equal importance. One such example would be mutations that reduce the effect of the sensitizing 
background, where GalphaS* is expressed in the post synaptic neuron. While a loss of function (lf) 
mutation in GalphaS* is unlikely (since it is expressed from a multi copy array), a mutation in type-IX 
adenylyl cyclase acy-1 (which is often identified in genetic screens as a suppressor of GαS*) would block 
all cell death in these animals, without being Glu-specific {70 and 71}. We will monitor for the presence 
of these mutations by checking the sequence of acy-1. The figure below shows the cell death pathway 
that plays a crucial role in our mutant strain (∆glt-3;nuIs5) 
 
 
 
 
 
 
   
    The mutants to which we will devote most of our attention will have normal Glu signaling (show no 
changes in response to nose touch or spontaneous mobility) and show normal paralysis time when 
tested for synaptic release. I will identify the genes that have these mutations by using whole-genome 
sequencing.  
Figure 11 
Figure 11: The schematic above is a depiction of the cell death pathway that involves our 
sensitized background and is crucial for nematode excitotoxicity. Mutations that result in the 
loss of function (lf) of key proteins along this pathway will either block or reduce the level of 
excitotoxic cell death. 
  
Materials and Methods 
  General Methods: C. elegans strains were grown and maintained on standard MYOB plates containing 
OP50 Escherichia coli bacteria at 20o obtained from our lab. All strains used were obtained from the C. 
elegans Consortium and were available to us ∆glt-3: ∆ glt3 (∆bz34)IV:nuIs (v), wild type (N2 var Bristol), 
ppk-1 (ok1411), glr-1 (ky176), Pglr-1 :: rfp transgene was obtained from Chris Rongo’s lab, eat-4 (ky5). 
 
Synchronization 
 20 ul of bleach solution was added onto an agar plate, using a 20-200 ul pipette without OP50. Gravid 
adult worms of our excitotoxicity strain (glt-3; nuIs5) were placed into the solution to release their eggs. 
Hatched worms were then transferred to standard MYOB plates with OP50 bacteria and incubated at 20 
degrees for a 1 day period to arrest animals at L1  {72}. 
 
Mutagenesis 
EMS is most effective at the time of generation of gametes, which occurs at the L4 stage of the parental 
P0. Once synchronized L4 worms were obtained, the plates were washed with 1ml of M9 solution into a 
16mL conical tube and 10 ul of EMS was added to bring the final concentration to 50mM. The P0 animals 
were exposed to EMS by swirling the tube at room temperature for 3 hours. When this was finished M9 
was used to wash the P0 animals 3 times, carefully removing the top solution. The P0 animals were then 
placed on 7 seeded plates with OP50 for 24 hours to allow them develop eggs carrying mutagenized 
chromosomes. The P0 animals were again bleached to obtain their F1 mutagenized eggs, eggs were 
allowed to hatch, and F1 mutagenized animals were arrested on a plate without food. These F1 animals 
were allowed to hatch over a 2 day period before they were transferred on to individual plates with 
food {62}.   These F1 single animals self-fertilized and generated F2 animals that were put on individual 
plates and screened for the presence of a subpopulation of animals with reduced or enhanced 
neurodegeneration (as would be expected of a recessive mutation).  
 
RNAi 
This is being done as a side project, and will therefore not be described in detail here. RNAi protocol was 
followed as described by the Ewald et al. {72}. I am currently crossing our excitotoxic strain glt-3; nuIs5 
with worms that have an RNAi sensitive background Punc-119::SID-1{60} and nre-1;lin-15B{59}. 
 
Behavior Analysis 
Nematode locomotion and worm paralysis by aldicarb were performed blindly, using standard protocol 
for behavior analysis. For Glu regulated forward and backward mobility we followed the protocol from 
V. Maricq’s lab (U. of Utah).  For aldicarb assay we followed Caldwell’s lab protocol (U. of Alabama) {73}. 
Standard MYOB plates were soaked with aldicarb and allowed to dry, bringing the final concentration to 
0.5mM. After the plates were dry, a spot of OP50 was placed in the center making it easier to score the 
animals as they become paralyzed. 25 freshly picked young adult worms from each strain were placed 
onto each plate. The percentage of paralyzed worms was scored every 10 minutes for a total of 1 hour.  
Each experiment was repeated 4 times. 
 
 
 
Analysis of Neurodegeneration 
We observed the extent of necrotic cell death in strains that express Gαs* by observing free-moving 
animals with an inverted scope under Nomaski Differential Interference Contrast (DIC). These animals 
were observed with no anesthetics on agar chunks with fresh nematode culture flipped over on the side. 
We scanned through the animals on the agar chunk, and in each animal we identified its developmental 
stage and counted degenerating neurons. Swollen cells in the nerve ring area were counted as head 
necrotic figures, representative of neurodegeneration {52}. In some cases we verified the identity of 
these swollen cells as glr-1expressing command interneurons by viewing Green Fluorescence Protein 
(GFP) expression (indicative that nuIs is functioning in these neurons since Gαs* and GFP are both 
expressed from the glr-1 promoter). ~50 animals for each developmental stage (L1-adult) were scored 
for the level of neurodegeneration. Statistical significance between control groups and experimental 
groups at L3 (typically the stage with highest levels of neurodegeneration) were analyzed using t-test 
score.  
 
Fluorescence Microscopy 
To identify possible changes in the level of expression of the key GluR subunit GLR-1, mutant strains 
were crossed with animals carrying an integrated construct of Pglr-1GLR-1::RFP {74}. From the F2 progeny 
of this cross we re-isolated glt-3; nuIs5 homozygous animals, and continued sib-selection to identify 
animals that show consistently reduced neurodegeneration (indicating they are also homozygous to the 
unidentified suppressor of neurodegeneration). Mutant animals that have Pglr-1 :: rfp transgene were 
mounted on a coverslip that had a drop of sodium azide ( a compound that paralyses worm after a few 
seconds of exposure), and observed on Nomaski Differential Interference Contrast (DIC) with 
epiflourescence  optics. Wild-type worms that expressed the rfp transgene were scored as 100 percent 
fluorescence, and rfp in other worms with smaller expression as less than 100 percent.  
 
Pharyngeal Pumping analysis  
I performed this assay as follows and used the protocol from previous studies {50} 
Adult worms are placed on seeded plates and allowed to lay eggs and shortly after, the adult worms are 
removed from the plate. The plates are then incubated at 20 degree Celsius for 3 days to synchronize all 
the animals. Adult worms are transferred onto freshly seeded plates and were allowed to move around 
the plate for 1 hour. After 1 hour the numbers of pulses are counted every 30 seconds under a 
dissecting microscope. The counts are repeated for 7 sessions with a total of 10 animals per session.  
 
 
 
 
 
 
 
 
 
 
  
Results 
   Classic EMS mutagenesis protocols {62} generate 1 strong loss-of-function (lf) mutation every 2,000-
10,000 genes. With ~20,000 genes/genome, and 2 genomes/animal, we expect ~5-20 mutations in each 
F1 mutagenized animal.  Random distribution of mutations suggests that 99% of the genes will have at 
least one mutation if there is an average of 4.6 mutations/gene. With ~20,000 genes in the genome, this 
requires us to obtain ~100,000 mutations to saturate the genome. With 5-20 strong mutations per 
animal, we will need to screen 5,000-20,000 F1 mutant animals to saturate the genome with at least 1 
mutation in every gene in a P=0.99. At this stage I therefore performed only a pilot screen (using 1,000 
animals, statistically covering at most ~50% of the genes).  I used our excitotoxicity strain glt-3; nuIs5 as 
my starting strain. After screening 1000 mutagenized F1 worms with our excitotoxicity background (glt-
3; nuIs5), we obtained several mutants with different phenotypes. The primary way through which we 
select mutants that are important to us is to visibly observe the changes in the level of 
Neurodegeneration and compare them to our starting strain (glt-3; nuIs5). I observed all the mutant 
strains that I obtained from doing EMS, and noted mutants that showed no change or increased or 
decreased levels of neurodegeneration when compared to our starting strain. Mutants that showed 
increased levels of excitotoxicity levels were not our immediate highest priority. As knockout mutations 
in genes that induce neuro-protection and are activated by Glu (e.g., DAF-16 and CREB) can result in 
exacerbated levels of neurodegeneration. Enhancer mutations are very important, but they are less 
likely to represent a direct trigger of excitotoxicity, and are, therefore, not as high priority to us as 
suppressor mutations.  
The graph below shows mutants strains that were obtained from our EMS screen. 
 
 
 
  
 
     
 
     
Figure 12 
Figure 12: The bar chart above shows the level of neurodegeneration of important strains obtained 
from EMS in comparison with our Excitotoxic model (∆glt-3; nuIs5) labelled as the starting strain. 
n>30, P> or = 0.01 for all suppressors 
and P=0.01 for enhancer 
= 0.01 
  The horizontal categories show the developmental stages of the worms, while the vertical axis shows 
the average number of neurons dying per head of the animal. A key note: we mainly care about 
neurodegeneration at L3 during development because at this stage all the glutamatergic synapses 
mature and neuronal Glu signaling is prominent. The signaling peaks at L3 and remains the same 
throughout the remaining stages of development (L4 and Adult). Although we observe a decrease in the 
number of vacuole like structures later on in development, this is primarily because the necrotic corpses 
are being cleared faster than they are being produced. As can be seen in the figure above, we have 
isolated 5 suppressor strains and 2 Enhancer strains. 
     
8 EMS strains that show interesting phenotypes have been isolated based on their change in 
neurodegeneration 
   
     I obtained a total of 8 excitotoxicity mutants; 5 of them showed suppressor phenotypes, one of them 
shows no neurodegeneration at all and 2 of them show an enhancer phenotype. All the strains were 
tested for normal Glu signaling and aldicarb sensitivity. 
 
 
 
 
 
 
 
 
 
  
 
IMN8:cny-8;glt-3;nuIs5 
 
   
 
 
 
    The strongest enhancer strain that showed up on our screen is IMN8 (cny-8; glt-3; nuIs5) as it shows 
significant increase in neurodegeneration at all stages. Figure 13 is a comparison of neurodegeneration 
levels between our mutant strain IMN8 and our starting strain ∆glt-3; nuIs5. 
 Figure 13:The bar graph in red depicts our enhancer mutant strain obtained from EMS (IMN8), while our 
starting strain (∆glt-3; nuIs5) highlighted in purple. At L3 both strains only show al significant difference in 
neurodegeneration level. 
Figure 13 
*** 
*** 
*** 
*** 
 
  
    
 
     Fig. 14 presents the Aldicarb assay for this mutant, showing the IMN8 is defective on Synaptic release, 
pointing to increased aldicarb sensitivity (short time to paralysis), suggesting an increased level of 
neurotransmitter being released into the synaptic cleft. 
 
 
Figure 14: Aldicarb analysis of our Enhancer mutant shows a defect in synaptic release (Quicker 
paralysis time); indicating that the phenotype observed may be as a result of a type 1 mutation.  
Figure 14 
  
 
 
Fig. 15 presents preliminary data on nose touch assays. It also shows no nose touch sensitivity in IMN8 
animals, suggesting that Glu signaling is defective in this strain, as mutant worms do not respond to this 
assay. The nose touch assay suggests that Glu receptor activity/expression may be affected by the cny-8 
mutation. 
Therefore, IMN8 exhibits increased neurodegeneration, increased synaptic release, and decreased 
function of Glu synapses. This combination is somewhat surprising; however, it is reminiscent of the 
phenotypes observed for glt-3 KO itself, where excess synaptic Glu causes increased neurodegeneration 
(compared to nuIs5), but reduced nose touch sensitivity due to the lingering effect of synaptic Glu. To 
test this idea we will perform additional tests such as mobility assays.  At the moment, the significance 
of this strain remains unclear. 
Figure 15 
Figure 15: The graph above shows that IMN8 is not responsive to nose touch when compared to our 
starting strain and mutants that are defective for GluR expression. This indicates that there is a 
mutation in Glu mediated behavioral circuitry (i.e a class 2 mutation).  
 IMN5:cny-5;glt-3;nuIs5 
 
 
 
 
Fig. 16 demonstrates that IMN5 shows somewhat increased levels of neurodegeneration during L3 larval 
stage. We next tested aldicarb-sensitive release and Glu signaling in this strain.   
 
 
Figure 16 
Figure 16: Comparison between our starting strain ( glt-3; nuIs5) and our mutant strain IMN5 show 
similar levels of neurodegeneration at L3. Although the difference is not statistically significant it was 
still treated as an enhancer mutation. 
** 
 
     
 
 
 
    
    Fig. 17 presents the aldicarb data for IMN5, and shows that our mutant has increased rate of paralysis, 
suggesting excessive synaptic release. 
  Aldicarb data for IMN5 show that our mutant has excessive synaptic release (similar to IMN8) and 
points to a type 1 mutation being the result of the slight increase in neurodegeneration levels.  
 
 
Figure 17 
Figure 17: The plot above depicts our enhancer strain IMN5 when exposed to aldicarb. As seen above 
IMN5 paralyzes relatively quicker than our sensitive control, indicating an increase in synaptic release. 
This tells us that our enhancer mutation may be as a result of an increase in synaptic release.  
  
 
 
  
 
      
The spontaneous mobility assay presented in Fig. 18 shows longer forward runs in IMN5, which is in line 
with reduced Glu signaling. This is somewhat surprising in light of the (slightly) increased levels of 
neurodegeneration and increase in synaptic release in this mutant. Although these are different assays, 
it is interesting to compare Glu activity in IMN8 and IMN5. Both strains have increased 
neurodegeneration, increased synaptic release, and reduced Glu signaling. However, in IMN8 Glu 
signaling is lower than that of glr-1 mutants (fig 15), while Glu signaling in IMN5 is midway between WT 
and glr-1 mutants. 
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Figure 18: Spontaneous mobility was performed for IMN5 and the results show that Glu signaling is 
affected in this mutant, indicating a mutation in behavioral circuitry, and possibly a type 2 mutation.  
 Suppressor Phenotypes 
 
IMN7:cny-7;glt-3;nuIs5 
   
 
 
 
Figure 19: The graph above is comparing the overall level of neurodegeneration of our suppressor strain 
(IMN7) with our starting strain ( glt-3; nuIs5). We see a significant decrease in the level of 
neurodegeneration at L3. 
Figure 19 
 
Fig. 19 shows significant decrease in the level of neurodegeneration in IMN7 at all stages including L3. 
This strain has the lowest levels of neurodegeneration amongst all suppressor strains isolated via EMS. 
Unfortunately, it had a viability problem and could not be maintained and studied further. This strain 
had a developmental defect that caused 70% percent of the worms to not hatch and reach adulthood. 
Eventually the strain was not viable and the data are preliminary as only 30 worms could be screened 
for neurodegeneration. 
 
IMN6:cny-6;glt-3;nuIs5 
Fig. 20 shows significant decrease in the level of neurodegeneration in IMN6 at L3 
 
 
Figure 20 
Figure 20: The graph above compared our suppressor strain (IMN6) in comparison with the starting strain 
( glt-3; nuIs5). Significant reduction of neurodegeneration was observed at L3, with the starting strain showing 
on average about 3.7 necrotic vacuoles per head and the suppressor strain showing on average 1.7 vacuoles 
per head.  
 
  
 
 
 
 
 
As seen in Fig. 21, Aldicarb data for IMN6 shows that these animals are relatively insensitive to paralysis, 
suggesting that synaptic release is reduced in this mutant  
      
Figure 21 
Figure 21: Aldicarb assay on IMN6 shows a defect in synaptic release. IMN6 appears resistant to Aldicarb 
when compared with our sensitive aldicarb strain ppk-1, indicating synaptic release is decreased in this 
mutant strain, hinting at a type 1 mutation. 
 
  
   
  
    As seen in fig 22, the nose touch sensitivity of IMN6 is decreased suggesting a decreased activity of 
Glu synapses (although the survival of command interneurons is probably increased). 
    Put together, the phenotype of IMN6 includes reduced neurodegeneration, reduced synaptic release, 
and reduced activity of glutamatergic synapses. This combination of phenotypes can be explained by 
reduced synaptic release leading to reduced synaptic Glu activity and reduced excitotoxicity (type 1).   
Figure 22 
Figure 22: The bar graph shown above compares Glu signaling in our suppressor strain, when compared to 
both the starting strain ( glt-3; nuIs5) and strains that are defective in Glu receptor expression (glr-1). It can 
be proposed from these results that our suppressor mutation strongly affects Glu circuitry, hinting at a type 
2 mutation. 
 IMN4:cny-4;glt-3;nuIs5 
 The fourth suppressor mutant that I identified during my screen is IMN4, another mutant that showed 
significant reduction in neurodegeneration at L3 (Fig. 23)  
 
 
 
    
  
   Since this mutant showed an interesting phenotype at L3 the next step was to perform Synaptic 
release and Glu signaling assays to categorize where this mutation fell in our outline (Synaptic, pre-
synaptic and post-synaptic). Preliminary data from aldicarb assays was not conclusive but showed a 
Figure 23 
Figure 23 shows the neurodegeneration levels of the suppressor strain IMN4; this mutant shows 
significant reduction in neurodegeneration at L3 with the mutant strain showing on average 1.7 
neurons dying per head of the animal and 3.8 neurons dying per head in our starting strain ( glt-
3; nuIs5). 
 
change in the level of synaptic release, indicating that our mutation affects neurotransmitter release 
and Glu receptor activity. 
 
 
 
 
   
 
  Fig. 24 shows that nose touch assay for IMN4, indicating a reduced sensitivity to nose touch and 
suggesting a reduced Glu synaptic activity. The data obtained from Glu signaling assay shows that our 
mutant phenotype affects Glu signaling, and may be a type 2 mutation that affects the overall 
activity/expression of Glu receptors on the post synaptic cell. Although we see a significant decrease in 
the level of neurodegeneration at L3, this phenotype can be attributed to the change in the reduced 
concentration or activity of Glu receptors in these mutants. Preliminary data from aldicarb assays also 
Figure 24 
Figure 24 shows the comparison between IMN4 and our starting strain ( glt-3;nuIs5) and strain that are mutant 
for Glu signaling. It can be seen from the graph that IMN4 is mutant for Glu signaling, and this could be the 
cause of the reduction of neurodegeneration phenotype. 
 
 
show a change in the level of synaptic release, indicating that our mutation affects neurotransmitter 
release and Glu receptor activity. 
 
IMN3:cny-3;glt-3;nuIs5 
 As seem in Fig. 25, another suppressor mutant is IMN3, as it shows significant decrease in the level of 
neurodegeneration throughout development (L1 - adult). Although this mutant looks interesting, it 
would have to be normal when tested for Glu signaling and synaptic release. 
 
 
 
 
Figure 25, shows another suppressor that was isolated from my EMS screen and it shows significant reduction 
in the level of neurodegeneration at L3 with 1.2 neurons dying per head of the animal in our mutant strain 
(IMN3) and 3.7 neurons dying per head of the animal in our starting strain ( glt-3;nuIs5). 
Figure 25 
 
  
 I next exposed these worms to aldicarb, to see if the synaptic release was affected. The result of this 
assay is shown below. 
 
 
 
 
 
   Fig. 26 indicates that IMN3 has an increased rate of paralysis in the aldicarb assay, suggesting that 
IMN3 may have a mutation that results in increased neurotransmitter release. We next performed Nose 
touch assay to see if this mutant is defective in Glu signaling. 
Figure 26 depicts the aldicarb data for my EMS mutant IMN3, the graph tells us that IM3 has a mutation in 
synaptic release due to its similarity to our control (ppk-1), which is very sensitive to Aldicarb and paralyzes 
relatively quickly when its exposed to aldicarb.  
Figure 26 
  
 
    Fig. 27 shows that the nose touch sensitivity of IMN3 is reduced, suggesting a reduced activity of Glu 
synapses. The combination of phenotypes for IMN3 is therefore surprising: reduced neurodegeneration, 
increased synaptic release, and reduced Glu responses. We therefore decided to test this strain further 
to ensure that we were performing Glu signaling assays correctly, and the results obtained were an 
indication of changes in either expression/activity of GluRs.  I made a cross between my mutant and 
another strain that had an extra chromosomal reporter fused with the promoter of Glr-1 (Pglr-1 ::: rfp) 
{74}. This reporter labels Glu receptor expression along the pharynx, allowing visual identification of 
changes in expression of these reporters. Fig. 28 shows the reporter expression in wild type and our 
mutant IMN3. 
 
 
Figure 27 shows Glu signaling assay (nose touch) results for IMN3. This result tells us that this mutant is 
defective for Glu signaling because the mutant does not respond to nose touch.  
     
   
     Figure 28 shows the overall expression of GLR-1::RFP in the wild type worm and our mutant EMS 
strain.  Our EMS mutant strain shows 50% decrease in the overall expression of GLR-1 in the nerve ring. 
We therefore conclude that the reduced neurodegeneration in IMN3 is likely due to reduced Glu 
receptor expression, while the reason for the increased synaptic release remains obscure. Nonetheless 
we classify IMN3 as a class 2 mutation 
 
 
 
 
 
 
Figure 28 shows the wild type strain with the transgene Pglr-1 ::: rfp on the left  and our mutant 
strain IMN3; Pglr-1 ::: rfp on the right. 
Figure 28 
 IMN2:cny-2;glt-3;nuIs5 
   As seen in fig 29, IMN2 shows steep decline in the levels of excitotoxicity. In combination with other 
assays (see below), we suggest that this mutant is a leading candidate with top priority because it shows 
reduced neurodegeneration throughout development in comparison to the starting strain while not 
reducing it below the level of neurodegeneration observed in nuIs5 (where acy-1 mediates Glu-
independent necrosis). 
 
 
 
 
Figure 29 shows another suppressor strain that shows significant levels of neurodegeneration.  
Figure 29 
 
  
 
 
 
 
   Fig. 30 presents the aldicarb assay for this mutant. These mutants show intersting results as they  
show similar paralysis time to our starting strain ( glt-3; nuIs5). Since this was the first mutant to show 
similar paralysis time to our starting strain, I used spontaneous mobility to test for Glu signaling. Since 
this assay is a more sensitive, I decided to use it and see if the mutant will show any changes in Glu 
signaling. 
Figure 30 Aldicarb assay results show IMN2 to be similar to our starting strain in terms of paralysis, 
indicating synaptic release is normal in this mutant strain. 
Figure 30 
  
 
  Fig. 31 shows that the spontaneous mobility of IMN2 animals is somewhat tilted towards forward 
mobility, suggesting reduced Glu activity. This mutant might therefore correspond to a type 2 mutation 
(peri-synaptic).  
Experimental Concerns 
   Although IMN2 is a very good candidate for whole genome sequencing, one major issue with our assay 
had to be dealt with. Although our aldicarb assay has shown no change in overall mechanism of synaptic 
release, it does not tell us if there is a specific defect in Glu release (e.g., due to a mutation in eat-4). To 
address this concern, we know from previous findings that Glu is used to control pharyngeal pumping in 
C. elegans. Pharyngeal muscle contraction is regulated by glutamate gated chloride channels, and 
mutations in eat-4, were shown to affect muscle contraction in the anterior pharynx {39}. In C. elegans, 
Figure 31 
Figure 31: Glu signaling for IMN2 appears to be altered. 
glr-1 
eat-4 is responsible for the packaging of Glu into vesicles via a proton exchange mechanism, and is 
important for regulating a variety of processes in the synapse. M3 cells in the pharynx use Glu as their 
neurotransmitter, and these receptors mediate pharyngeal pumping by using Chloride channels 
expressed by AVR-15{75}. Once the receptor is activated by Glutamate, chloride ions move into the cell 
and causes hyperpolarization. We used this study to our advantage, and tested if our IMN2 mutation 
showed a phenotype as a result of an eat-4 mutation. Protocol for pharyngeal pumping is described in 
the methods section. 
 
 
 
   Figure 32: Pharyngeal pumping appears normal in IMN2 mutant worms, indicating eat-4 function is 
normal. 
Figure 32 
   We can conclude that the reduction in Neurodegeneration phenotype is not as a result of a mutation 
in eat-4, as the pumping rate of our mutant is not different statistically from the starting strain. This 
makes IMN2 a very important candidate for sequencing, and an impressive mutant. 
 
IMN1:cny-1;glt-3;nuIs5 
  This strain does not show any necrotic vacuole-like structures in the nerve ring, indicating that the 
mutation is affecting the cell death pathway dramatically. However, the extensive effect also suppresses 
our background neurodegeneration observed in nuIs5 which is independent of Glu. Therefore this 
mutation may not be our top priority.  
Aldicarb and Glu signaling assay results are shown below. 
 
 
Figure 33: IMN1 shows similar paralysis time to our starting strain, indicating synaptic release is normal 
Figure 33 
  
As shown in Fig. 33 Aldicarb results show that synaptic release is normal in terms of synaptic release. 
  
 
 
 
 Figure 34 shows Glu signaling assay for IMN1. However, the complete lack of neurodegeneration is 
similar to that seen in acy-1 mutants. Therefore, although this mutant shows some interesting results, a 
follow up of possible mutations in the cell death pathway is required before further conclusions can be 
made.  
 
 
 
 
Figure 34: Glu signaling assay for IMN1 show similar results to our starting strain, indicating Glu 
signaling is normal. 
Figure 34 
  
 
 
A tabular representation of all assays performed on mutant candidates is shown below. 
 
 
 
 
 
Mutants Excitotoxic Level when 
compared to starting 
(∆glt-3;nuIs5) 
Synaptic release 
(Aldicarb sensitivity) 
Glutamate Signaling 
(Nose touch and 
forward backward 
mobility) 
IMN1 None  Normal Normal 
IMN2 Reduced  Normal Normal 
IMN3 Reduced  Increased Reduced 
IMN4 Reduced  Increased Reduced 
IMN5 Increased  Increased Normal 
IMN6 Reduced  Reduced Reduced 
IMN7 Reduced Could not be 
performed 
Could not be 
performed 
IMN8 Increased  Increased Reduced 
  
Discussion 
    Genetic screens are the cornerstone of unbiased research, and have been used to understand 
different pathways that regulate a variety of processes in Drosophila, yeast and C. elegans. To study the 
process of excitotoxicity, we created a nematode model that has a knockout of glt-3 in combination with 
a sensitive background GalphaS (GαS*) and performed a genetic screen on this strain. The main goal for 
using a genetic screen was to obtain mutants that showed an overall decrease in neurodegeneration, 
and were having an effect in the post-synaptic cell.  We used mutagenesis to induce random mutations 
in the genome of our construct, and screen 1000 worms for phenotypes that show a change in the levels 
of excitotoxicity.  
    We have identified 8 mutants; 6 of them show suppressor phenotypes, and 2 show an Enhancer 
phenotype.  Once the mutants were identified; they were classified into different functional groups to 
have an understanding of where in the synapse our mutations were having an effect. We tested this by 
performing synaptic release assays using the drug aldicarb, and mutants that showed a defective 
phenotype were grouped according to their corresponding class of mutations e.g. Class 1. Mutants were 
also tested for Glu signaling using nose touch and forward and backward mobility tests, to see if 
mutants were defective in Glu receptor expression. We also identified a mutant that showed no 
neurodegeneration, but have an idea that this mutation is affecting the cell death pathway post 
synaptically independent of Glu and is not important to us. We did identify 2 mutants that showed 
interesting phenotypes; IMN8 and IMN2 are interesting candidates. IMN8 is defective in synaptic release 
and Glu signaling, but still shows increased levels of neurodegeneration. This mutation could result in 
phenotypes that could compensate each other, and may seem like type and type 2 mutations but may 
not be the case. Mutations that result in increased Glu release could over stimulate the GluRs and result 
in reduced Glu signaling because these receptors become desensitized and unavailable to new 
stimulation. The other possibility that could occur would be, the increase in Glu release from the pre-
synaptic cell could be a compensatory mechanism for the lack of Glu receptors on the post synaptic cell. 
These behaviors have been observed in synapses, where receptor expression were reduced due to 
mutations or developmental defects, hinting at this also occurring in our mutant strains that showed 
increased neurotransmitter release and reduced response to nose touch.  We will pinpoint the molecular 
basis of this mutation by genetic mapping and then doing whole genome sequencing.  
    IMN2 is our suppressor mutant that is normal for synaptic release, and Glu signaling while showing a 
decrease in neurodegeneration. This mutant is very important to us as we have a mutant strain that 
shows reduced neurodegeneration and is normal for all assays.  
     Although we have two mutants that show interesting phenotypes, the other mutants we screened 
are not useless. They were very informative and tell us that we are doing the screen correctly because 
we expect mutations in certain areas to affect synaptic release and Glu receptor expression, and we see 
these mutations in some mutants. Furthermore we could collaborate with research groups that 
specialize in the study of neurotransmitter release or GluR expression. 
 
 
 
 
 
 
 
 
Future Experiments 
 Since we have two mutants that show interesting phenotype from my screen, the next steps for EMS 
mutants will be 
a) Backcrossing these mutants with our starting strain (∆glt-3; nuIs5) and re-isolating our mutation to 
remove any other mutations in the background. 
b) Sending both strains to sequencing once they are backcrossed 
c) Positional mapping with SNP can also be done on these mutants by crossing IMN2 and IMN8 to a 
Hawaiian background strain that has our excitotoxicity setup 
d) RNAi to knockdown specific genes in our sensitized background strain and observe which gene has a 
pronounced effect on neurodegeneration. 
e) Identifying if the mutation in IMN-1 is caused by a knockout of AC-9 by PCR and sequencing. 
f) Using Differential Interference Contrast with epiflourescence optics to observe surviving neurons in 
the RIG area of our mutant strain IMN2. 
g) Classifying mutants with similar phenotypes into complementation groups. E.g., IMN8 and IMN5 show 
similar phenotypes, and may be allelic to each other. Crossing these two strains together and seeing if 
they complement or not will tell us if these mutations are present on the same or different genes.  
 
 
 
 
 
 Conclusion 
    Using a genetic screen to understand key steps in a pathway grants us an unbiased approach to 
understanding central mediators that are involved in these pathways. Although this method has its 
drawbacks, its insight into key processes cannot be undermined. We used genetic screens to induce 
random mutations in the nematode worms that have Excitotoxic-like conditions in the genome, and 
have identified several strains that have a change in their levels of excitotoxicity. These mutants were 
tested for changes in neurotransmitter release by using the drug aldicarb (An acetyl cholinesterase 
inhibitor) and Glu signaling by doing Nose touch and Spontaneous mobility. Mutants that showed 
defects in these areas were classified into functional groups based on the phenotypes that were 
observed from the assays. Only mutations that did not affect the presynaptic architecture and still 
showed reduced levels of excitotoxicity were given top priority. Future understanding of these mutants 
will be very important for understanding key processes in nematode excitotoxicity, and provide insight 
into similar processes happening in mammals. 
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